Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Latest From Acrux, Ltd.

The Quality Lowdown: Quality Vision Falls Short At Various US and Indian Facilities

Court overrides stem cell clinic’s dismissal of drug GMPs, the US FDA upbraids drug makers for quality unit shortfalls, and a variety of snafus trigger drug recalls.

Manufacturing Quality

A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors

Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.

BioPharmaceutical Clinical Trials

Australia Earnings Roundup: CSL, Acrux, Pharmaxis, Mesoblast (Part 1)

PharmAsia News combs through earnings reports to bring you highlights on Australian biotech firms. We start with CSL Ltd, Acrux, Pharmaxis and Mesoblast for the period ended Dec. 31, 2012.

BioPharmaceutical Australia

Hunter to merge with Probiomics as it seeks partner for Phase II COPD vaccine

Public unlisted Australian drug development company Hunter Immunology is recommending that its shareholders accept the takeover offer from listed biotech firm Probiomics.

Infectious Diseases Respiratory
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Other Names / Subsidiaries
    • FemPharm Pty